EA202192607A1 - Композиции и способы для лечения глазного заболевания - Google Patents

Композиции и способы для лечения глазного заболевания

Info

Publication number
EA202192607A1
EA202192607A1 EA202192607A EA202192607A EA202192607A1 EA 202192607 A1 EA202192607 A1 EA 202192607A1 EA 202192607 A EA202192607 A EA 202192607A EA 202192607 A EA202192607 A EA 202192607A EA 202192607 A1 EA202192607 A1 EA 202192607A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
treatment
once
eye disease
Prior art date
Application number
EA202192607A
Other languages
English (en)
Russian (ru)
Inventor
Ниранджан Б. Пандей
Original Assignee
Асклепикс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Асклепикс Терапьютикс, Инк. filed Critical Асклепикс Терапьютикс, Инк.
Publication of EA202192607A1 publication Critical patent/EA202192607A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EA202192607A 2019-03-26 2020-03-26 Композиции и способы для лечения глазного заболевания EA202192607A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962824017P 2019-03-26 2019-03-26
PCT/US2020/024972 WO2020198481A1 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease

Publications (1)

Publication Number Publication Date
EA202192607A1 true EA202192607A1 (ru) 2022-03-03

Family

ID=72609544

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192607A EA202192607A1 (ru) 2019-03-26 2020-03-26 Композиции и способы для лечения глазного заболевания

Country Status (12)

Country Link
US (1) US12540171B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946418A4 (cg-RX-API-DMAC7.html)
JP (1) JP7650074B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210146352A (cg-RX-API-DMAC7.html)
CN (1) CN113710264A (cg-RX-API-DMAC7.html)
AU (1) AU2020248438A1 (cg-RX-API-DMAC7.html)
CA (1) CA3134816A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192607A1 (cg-RX-API-DMAC7.html)
IL (1) IL286625A (cg-RX-API-DMAC7.html)
MX (1) MX2021011727A (cg-RX-API-DMAC7.html)
WO (1) WO2020198481A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107235B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2015781A4 (en) * 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
EP2649095B1 (en) * 2010-12-10 2021-10-06 Aleksander S. Popel Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
JP6470740B2 (ja) * 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
CN108883150A (zh) 2015-11-19 2018-11-23 阿斯克雷佩西治疗公司 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
US20200179285A1 (en) * 2017-05-08 2020-06-11 The Johns Hopkins University Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
EP3661536A4 (en) * 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESS FOR IDENTIFICATION AND MANUFACTURING OF PHARMACEUTICAL INGREDIENTS FOR ACTIVATING A TIE2 RECEPTOR

Also Published As

Publication number Publication date
KR20210146352A (ko) 2021-12-03
AU2020248438A1 (en) 2021-10-28
ZA202107235B (en) 2023-10-25
WO2020198481A1 (en) 2020-10-01
CA3134816A1 (en) 2020-10-01
EP3946418A4 (en) 2023-02-22
US12540171B2 (en) 2026-02-03
JP7650074B2 (ja) 2025-03-24
US20230054032A1 (en) 2023-02-23
CN113710264A (zh) 2021-11-26
IL286625A (en) 2021-12-01
MX2021011727A (es) 2022-01-24
JP2022527276A (ja) 2022-06-01
EP3946418A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
EA202192607A1 (ru) Композиции и способы для лечения глазного заболевания
MX383971B (es) Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan.
RU2012140704A (ru) Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция
JP2017515811A5 (cg-RX-API-DMAC7.html)
NO980195L (no) Cyklosporinderivater med anti-HIV-effekt
JP2018504984A5 (cg-RX-API-DMAC7.html)
AU2016258001B2 (en) Injectable depot formulations
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
PH12021551232A1 (en) Haloallylamine compounds and application thereof
WO2020099925A3 (en) Peptides and pharmaceutical compositions for treating eye diseases
TW200518760A (en) Triamcinolone acetonide and anecortave acetate formulations for injection
RU2006142861A (ru) Применение вязкоупругой композиции по новому назначению
AR123570A1 (es) Tratamientos para el edema macular diabético y la agudeza visual disminuida
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
Bork et al. Icatibant
ES2672099T3 (es) Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
WO2006119128A3 (en) Vascular targeting of ocular neovascularization
JOP20240112A1 (ar) طريقة علاج الضمور الجغرافي باستخدام ناقل العلاج الجيني الذي يعبر عن cd59 القابل للذوبان
JP2018536650A5 (cg-RX-API-DMAC7.html)
BR112022004535A2 (pt) Formulações de entrega de fármaco
EA202191130A1 (ru) Фармацевтическая композиция для лечения апластической анемии
GB0716600D0 (en) Ophthalmic medicine composition
AU2012237066B2 (en) Pharmaceutical composition for preventing or treating macular degeneration
KR20250067950A (ko) 안과 질환의 치료를 위한 킬레이트제, 침투 증강제 및 히드록시에틸 셀룰로스를 포함하는 제제
MX2021015796A (es) Composiciones y metodos para tratar enfermedades oculares.